Early combination of albumin with crystalloids administration might be beneficial for the survival of septic patients: a retrospective analysis from MIMIC-IV database

Annals of Intensive Care

Table 2 Primary and secondary outcomes

Outcomes	Crystalloids (n = 6597)		Combination (n = 920)		Difference (95%CI)	P
Outcomes	Values	95%CI	Values	95%CI	Difference (95%CI)	P
Before PSM
RMST for 28 days (days)	23.37	23.12–23.61	25.10	24.6–25.6	1.73 (1.17–2.29)	< 0.001
RMST for 60 days (days)	46.09	45.31–46.88	50.93	49.37–52.49	4.84 (3.09–6.58)	< 0.001
LOS ICU (days)	6.65	6.47–6.83	10.37	9.65–11.09	3.72 (2.98–4.46)	< 0.001
LOS Hospital (days)	14.32	13.93–14.71	19.03	18.00–20.07	4.72 (3.61–5.82)	< 0.001
Total volume of crystalloids (L)	2.37	2.27–2.41	3.11	2.84–3.40	0.78 (0.49–1.07)	< 0.001
After PSM (1:1)
RMST for 28 days (days)	22.20	21.53–22.86	25.10	24.60–25.60	3.23 (2.38–4.08)	< 0.001
RMST for 60 days (days)	42.18	40.09–44.27	50.93	49.37–52.49	9.09 (6.49–11.69)	< 0.001
LOS ICU (days)	7.73	7.25–8.21	10.37	9.65–11.08	2.64 (1.77–3.50)	< 0.001
LOS Hospital (days)	15.21	14.89–17.44	19.04	18.00–20.07	2.88 (1.24–4.52)	< 0.001
Total volume of crystalloids (L)	2.76	2.46–3.06	3.11	2.84–3.40	0.36 (-0.05–0.77)	0.085

RMST (days) means the restricted mean survival time in each group during the first 28 and 60 days after ICU admission. The difference in RMST (95%CI) was calculated with the difference of restricted mean survival time between the two groups (RMST_combination-RMST_crystalloids), which means the increment or reduction of survival owing to the combination therapy. LOS ICU Length of ICU stay, LOS Hospital Length of hospital stay, PSM propensity score matching